There is not much to worry about in IHL land in my view. IHL-42x should eventually either be snapped up or commercialised to take enough market share to boost our share price dramatically. The drug has already been validated in humans, so the riskiest part has been passed with flying colours.
We are fully cashed up to progress trials to, and beyond inflection points.
Ann: Loyalty Option Issue Raises $23.6M, page-109
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)